Susan Galbraith, AstraZeneca EVP, oncology R&D, at EUBIO22 (Rachel Kiki for Endpoints News)
Updated: AstraZeneca jumps deeper into cell therapy 2.0 space with $320M biotech M&A
Right from the start, the execs at Neogene had some lofty goals in mind when they decided to try their hand at a cell therapy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
